Verismo Therapeutics, Inc.
Last verified 2026-05-21. JSON
| Total raised | $28.0M |
|---|---|
| Latest round | Funding round, $28.0M, 2026-04-21 |
| Founded | 2020 |
| Headquarters | Philadelphia, PA |
| Industry | other health care |
| Stage | unknown |
| Website | verismotherapeutics.com |
Verismo Therapeutics develops CAR T cell therapies for solid tumors using its KIR-CAR (SynKIR) multi-chain immunoreceptor platform. It aims to treat patients whose solid tumors resist single-chain CAR T approaches. Modeled on NK-cell receptors, the construct reduces the T-cell exhaustion that limits earlier therapies.
Funding rounds
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2026-04-21 | Funding round | $28.0M | undisclosed |
Detected tech stack
Cloudflare, WordPress, Yoast SEO 27.6, GoDaddy CoBlocks, Google Tag Manager, jQuery Migrate 3.4.1, parallax.js 1.5, PHP, Cloudflare Bot Management, OWL Carousel, web-vitals, MySQL
Provenance
| Fact | Status | Basis |
|---|---|---|
| Funding round, $28.0M | sourced | SEC EDGAR named as publisher. Document, retrieved 2026-09-25. |
| Total raised $28.0M | sourced | SEC EDGAR named as publisher. Document, retrieved 2026-09-25. |
| Company existence | self-reported | verismotherapeutics.com, read 2026-05-21 |
| Description | self-reported | verismotherapeutics.com, read 2026-05-21 |
Change history
| Date | Fact | Change | Basis |
|---|---|---|---|
| 2026-09-25Latest round: seed, $28.0M, 2026-04-21 → Funding round, $28.0M, 2026-04-21, SEC EDGAR, document, retrieved 2026-09-25 | Latest round | seed, $28.0M, 2026-04-21 → Funding round, $28.0M, 2026-04-21 | SEC EDGAR, document, retrieved 2026-09-25 |
| 2026-09-25Round: attributed → sourced, SEC EDGAR, document, retrieved 2026-09-25 | Round | attributed → sourced | SEC EDGAR, document, retrieved 2026-09-25 |
Records begin 2026-09-24. All changes